Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  trastuzumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 249 for your search:
Start Over
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18530, NCT00127933
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25477, NCT01260194
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25288, NCT01301729
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
Trastuzumab in Treating Women With Primary Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO16348, BIG-01-01, EU-20216, ROCHE-B016348E, ROCHE-B016348C, EORTC-10011, CAN-NCIC-MA24, IBCSG-28-02, MA24, NCT00045032
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000257580, P30CA016042, UCLA-0109024, BCIRG-007, ROCHE-UCLA-0109024, GENENTECH-UCLA-0109024, NCI-G02-2116, NCT00047255
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 64
Sponsor: Other
Protocol IDs: UC-0140/0005 - PACS 04, FRE-FNCLCC-PACS-04/0005, EU-20236, PACS04, NCT00054587
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000334899, S0221, U10CA032102, SWOG-S0221, NCT00070564
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: ID99-146, NCT00038402
Phase III Randomized Study of Vinorelbine With or Without Trastuzumab (Herceptin®) in Women With HER2-Positive Progressive Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0347, S0347, NCT00103233
TBP Study With Capecitabine Plus Minus Trastuzumab
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 26, BIG3-05, NCT00148876
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF104383, NCT00272987
Trial of Myocet in Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 an over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STM01-102, NCT00294996
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF104900, NCT00320385
Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000509793, INCA-PHARE, INCA-RECF0146, EUDRACT-2006-000070-67, PHARE, NCT00381901
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO20231, NCT00391092
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18742, NCT00448279
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: M06HER, 2006-001707-11, NCT00459771
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NSABP B-41, NCT00486668
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: EGF106708, NCCTG-N063D, N063D, BIG 2-06, MAC.13, NCT00490139
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00341, CDR0000559039, ACOSOG-Z1041, Z1041, U10CA012027, NCT00513292
First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00504, CDR0000561762, E1105, U10CA180820, U10CA021115, ECOG-E1105, NCT00520975
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF106903, NCT00553358
Start Over